Profectus Biosciences, Inc.

Baltimore, MD 21224

SBIR Award Summary

Total Number of Awards 30
Total Value of Awards $17.6MM
First Award Date 06/01/07
Most Recent Award Date 08/01/17

Key Personnel

Last Name Name Awards Contact
Bagley Kenneth C Bagley 11
Eldridge John Hayward Eldridge 1
Fouts Timothy R Fouts 15
Dimitrov Antony Dimitrov 2
SCHWARTZ JENNIFER A SCHWARTZ 1

30 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/17 - 07/31/18

DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 07/01/17 - 06/30/18

? DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists of gp120 derived from HIV-1 genetically linked via a 20 amino acid linker to the D1D2 domains of human CD4. When rhesus macaques were inoculate...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 06/06/17 - 05/31/18

Abstract IgE-mediated food allergies have become a major public health concern, now estimated to affect 6-8% of children under 4 years old and 4% of adults in the US. Approximately 200,000 emergency hospital visits are caused from allergic reactions to foods annually, with at least 150 fatalities resulting from anaphylaxis. The overall economic ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/16 - 07/31/17

DESCRIPTION: Based on the prevailing evidence, we believe that a highly effective vaccine for HIV prophylaxis must induce long-lasting, broadly cross-reactive antibody responses to envelope that exhibit antiviral activity, as well as multi-antigen, polyfunctional CD4+ and CD8+ T cell responses that produce antiviral chemokines and cytokines and ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/16 - 07/31/17

DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 07/01/16 - 06/30/17

? DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists of gp120 derived from HIV-1 genetically linked via a 20 amino acid linker to the D1D2 domains of human CD4. When rhesus macaques were inoculated...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 06/15/16 - 05/31/17

ABSTRACTA universal influenza vaccine is believed to be possible if conserved regions of influenza are effectively targetedand appropriate immune responses are generated against those targets. The enhanced safety, stability, andaccelerated product development generally provided by DNA vaccination make it an appealing approach todevelop such a un...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/21/15 - 07/31/16

DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/15 - 07/31/16

DESCRIPTION: Based on the prevailing evidence, we believe that a highly effective vaccine for HIV prophylaxis must induce long-lasting, broadly cross-reactive antibody responses to envelope that exhibit antiviral activity, as well as multi-antigen, polyfunctional CD4+ and CD8+ T cell responses that produce antiviral chemokines and cytokines and ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists of gp120 derived from HIV-1(BaL) genetically linked via a 20 amino acid linker to the D1D2 domains of human CD4. Rhesus macaques were inoculated wit...

Load More